These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Programmed Cell Death Ligand 1 Expression in Canine Cancer. Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075 [TBL] [Abstract][Full Text] [Related]
24. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389 [TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326 [TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204 [TBL] [Abstract][Full Text] [Related]
27. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431 [TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. Yvorel V; Patoir A; Casteillo F; Tissot C; Fournel P; Stachowicz ML; Karpathiou G; Tiffet O; Péoc'h M; Forest F PLoS One; 2017; 12(7):e0180346. PubMed ID: 28671973 [TBL] [Abstract][Full Text] [Related]
29. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388 [TBL] [Abstract][Full Text] [Related]
30. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186 [TBL] [Abstract][Full Text] [Related]
31. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470 [TBL] [Abstract][Full Text] [Related]
32. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related]
33. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas. Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910 [TBL] [Abstract][Full Text] [Related]
34. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions. Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249 [TBL] [Abstract][Full Text] [Related]
35. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103 [TBL] [Abstract][Full Text] [Related]